[Diabetes mellitus as a complication of treatment with atypical neuroleptics. Possible pathomechanisms and treatment recommendations]
Standard
[Diabetes mellitus as a complication of treatment with atypical neuroleptics. Possible pathomechanisms and treatment recommendations]. / Jahn, Holger; Schneider, T.
in: NERVENARZT, Jahrgang 75, Nr. 5, 5, 2004, S. 442-450.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - [Diabetes mellitus as a complication of treatment with atypical neuroleptics. Possible pathomechanisms and treatment recommendations]
AU - Jahn, Holger
AU - Schneider, T
PY - 2004
Y1 - 2004
N2 - An increased risk for occurrence of diabetic metabolic states has been reported for treatment with atypical antipsychotics. Initial studies suggest that atypical antipsychotics as a heterogeneous group of substances are not equally concerned. An increased risk for development of diabetes mellitus can be assumed for clozapine and olanzapine, while other atypical and conventional antipsychotics seem to carry only a slightly elevated risk. It remains as yet unresolved whether there is a causal connection or whether other not yet identified factors are involved. However, atypical antipsychotics intervene in various ways in glucose and fatty acid metabolism due to their broad receptor profile.We suggest that some atypical antipsychotics disturb regulatory loops of fat metabolism in fatty tissue and muscle,which may result in insulin resistance and finally diabetes. Changes in leptin release and development of leptin resistance possibly play an important role. These new results should be considered when planning therapy, although a final risk analysis is not yet possible.
AB - An increased risk for occurrence of diabetic metabolic states has been reported for treatment with atypical antipsychotics. Initial studies suggest that atypical antipsychotics as a heterogeneous group of substances are not equally concerned. An increased risk for development of diabetes mellitus can be assumed for clozapine and olanzapine, while other atypical and conventional antipsychotics seem to carry only a slightly elevated risk. It remains as yet unresolved whether there is a causal connection or whether other not yet identified factors are involved. However, atypical antipsychotics intervene in various ways in glucose and fatty acid metabolism due to their broad receptor profile.We suggest that some atypical antipsychotics disturb regulatory loops of fat metabolism in fatty tissue and muscle,which may result in insulin resistance and finally diabetes. Changes in leptin release and development of leptin resistance possibly play an important role. These new results should be considered when planning therapy, although a final risk analysis is not yet possible.
M3 - SCORING: Zeitschriftenaufsatz
VL - 75
SP - 442
EP - 450
JO - NERVENARZT
JF - NERVENARZT
SN - 0028-2804
IS - 5
M1 - 5
ER -